subject: Cynapsus Therapeutics, Inc. (cth) - Financial And Strategic Swot Analysis Review [print this page] Cynapsus Therapeutics IncCynapsus Therapeutics Inc. (formerly Cannasat Therapeutics, Inc.) is pharmaceutical company, that is engaged in the discovery and development of therapeutics for the treatment of neuropathic pain, schizophrenia, chemotherapy-induced nausea and vomiting and other CNS related disorders. The companys product pipeline includes relivar, currently in the second phase of phase I clinical trial for symptomatic management of neuropathic pain; and modulyn, currently in Phase 2 trial for the treatment of schizophrenia. Another major pipeline product is APL-130277 for the treatment of parkinsons disease. It is also involved in developing a formulation technology for cannabinoid drug candidates that may be used in treating neuropathic pain associated with multiple sclerosis and cancer. Recently, the company name is changed to Cynapsus Therapeutics Inc. Cannasat is headquartered in Toronto, Canada. (
Cynapsus Therapeutics, Inc. Key Recent Developments
Aug 22, 2011: Cynapsus Therapeutics Reports Q2 2011 Results
Jun 17, 2011: Cynapsus Therapeutics Reports Q1 2011 Results
Mar 07, 2011: Cynapsus Therapeutics Reports 2010 Results
Mar 22, 2011: Cynapsus Elects Rochelle Stenzler As New Chairperson
Nov 10, 2011: Cynapsus Therapeutics Reports Q3 2011 Results
This comprehensive SWOT profile of Cynapsus Therapeutics, Inc. provides you an in-depth strategic analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of GlobalDatas Profile on Demand service, covering over 50,000 of the worlds leading companies. Once purchased, GlobalDatas highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Cynapsus Therapeutics, Inc. including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).
The profile contains critical company information including*,
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
